Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 6/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2390006 | 0.92 | MAPKAPK5 (0.41) | MAPKAPK5SYKTLR9TLR8TLR7 | |
| SCHEMBL2389685 | 0.86 | MAPKAPK5 (0.64) | MAPKAPK5SYKTLR9TLR8TLR7 | |
| SCHEMBL1570378 | 0.86 | MAPKAPK5 (0.66) | MAPKAPK5SYK | |
| SCHEMBL1475075 | 0.82 | MAPKAPK5 (0.60) | MAPKAPK5TTK | |
| SCHEMBL1570305 | 0.80 | SYK (0.43) | MAPKAPK5SYKTLR9TLR8TLR7 | |
| SCHEMBL1476826 | 0.80 | MAPKAPK5 (0.49) | MAPKAPK5TTK | |
| SCHEMBL1477008 | 0.79 | MAPKAPK5 (0.72) | MAPKAPK5 | |
| SCHEMBL2390008 | 0.78 | MAPKAPK5 (0.57) | MAPKAPK5SYK | |
| Glpg-0259 SCHEMBL12661679 | 0.78 | MAPKAPK5 (0.49) | MAPKAPK5SYKTLR9TLR8TLR7 | |
| Glpg-0259 SCHEMBL1889564 | 0.78 | MAPKAPK5 (0.49) | MAPKAPK5SYKTLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | claimed |
| US-8012983-B2 | Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL1B, IL1A, PTGER1 | MAPKAPK5 131/4885SYK 3339/4885TLR9 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.